P2Y2 receptor agonists for the treatment of dry eye disease: a review

Oliver C F Lau,1 Chameen Samarawickrama,1,2 Simon E Skalicky1–31Sydney Eye Hospital, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia; 3Ophthalmology Department, Addenbrooke's Hospital, Cambridge, United KingdomAbstract: Recent advances i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lau OCF, Samarawickrama C, Skalicky SE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/4799069f8e634a2d99c76a02cad313ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4799069f8e634a2d99c76a02cad313ea
record_format	dspace
spelling	oai:doaj.org-article:4799069f8e634a2d99c76a02cad313ea2021-12-02T04:57:11ZP2Y2 receptor agonists for the treatment of dry eye disease: a review1177-5483https://doaj.org/article/4799069f8e634a2d99c76a02cad313ea2014-01-01T00:00:00Zhttp://www.dovepress.com/p2y2-receptor-agonists-for-the-treatment-of-dry-eye-disease-a-review-a15662https://doaj.org/toc/1177-5483 Oliver C F Lau,1 Chameen Samarawickrama,1,2 Simon E Skalicky1–31Sydney Eye Hospital, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia; 3Ophthalmology Department, Addenbrooke's Hospital, Cambridge, United KingdomAbstract: Recent advances in the understanding of dry eye disease (DED) have revealed previously unexplored targets for drug therapy. One of these drugs is diquafosol, a uridine nucleotide analog that is an agonist of the P2Y2 receptor. Several randomized controlled trials have demonstrated that the application of topical diquafosol significantly improves objective markers of DED such as corneal and conjunctival fluorescein staining and, in some studies, tear film break-up time and Schirmer test scores. However, this has been accompanied by only partial improvement in patient symptoms. Although evidence from the literature is still relatively limited, early studies have suggested that diquafosol has a role in the management of DED. Additional studies would be helpful to delineate how different subgroups of DED respond to diquafosol. The therapeutic combination of diquafosol with other topical agents also warrants further investigation.Keywords: dry eye disease, meibomian gland disease, aqueous tear deficiency, diquafosol, P2Y2 agonistsLau OCFSamarawickrama CSkalicky SEDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 327-334 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Lau OCF Samarawickrama C Skalicky SE P2Y2 receptor agonists for the treatment of dry eye disease: a review
description	Oliver C F Lau,1 Chameen Samarawickrama,1,2 Simon E Skalicky1–31Sydney Eye Hospital, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia; 3Ophthalmology Department, Addenbrooke's Hospital, Cambridge, United KingdomAbstract: Recent advances in the understanding of dry eye disease (DED) have revealed previously unexplored targets for drug therapy. One of these drugs is diquafosol, a uridine nucleotide analog that is an agonist of the P2Y2 receptor. Several randomized controlled trials have demonstrated that the application of topical diquafosol significantly improves objective markers of DED such as corneal and conjunctival fluorescein staining and, in some studies, tear film break-up time and Schirmer test scores. However, this has been accompanied by only partial improvement in patient symptoms. Although evidence from the literature is still relatively limited, early studies have suggested that diquafosol has a role in the management of DED. Additional studies would be helpful to delineate how different subgroups of DED respond to diquafosol. The therapeutic combination of diquafosol with other topical agents also warrants further investigation.Keywords: dry eye disease, meibomian gland disease, aqueous tear deficiency, diquafosol, P2Y2 agonists
format	article
author	Lau OCF Samarawickrama C Skalicky SE
author_facet	Lau OCF Samarawickrama C Skalicky SE
author_sort	Lau OCF
title	P2Y2 receptor agonists for the treatment of dry eye disease: a review
title_short	P2Y2 receptor agonists for the treatment of dry eye disease: a review
title_full	P2Y2 receptor agonists for the treatment of dry eye disease: a review
title_fullStr	P2Y2 receptor agonists for the treatment of dry eye disease: a review
title_full_unstemmed	P2Y2 receptor agonists for the treatment of dry eye disease: a review
title_sort	p2y2 receptor agonists for the treatment of dry eye disease: a review
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/4799069f8e634a2d99c76a02cad313ea
work_keys_str_mv	AT lauocf p2y2receptoragonistsforthetreatmentofdryeyediseaseareview AT samarawickramac p2y2receptoragonistsforthetreatmentofdryeyediseaseareview AT skalickyse p2y2receptoragonistsforthetreatmentofdryeyediseaseareview
_version_	1718400944660545536

P2Y2 receptor agonists for the treatment of dry eye disease: a review

Ejemplares similares